secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211850
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis Q1 clinical test volume +258% YoY to 7,815; secures Medicare coverage for lung cancer
--------------------------------------------------------------------------------

- Revenue $15.5M vs $20.6M YoY; clinical revenue $1.4M vs $0.3M as non-core revenue declined.
- Cash, equivalents & short-term investments $233.2M; includes ~$21M net from ATM at $10.00/share.
- Full-year 2026 guidance reaffirmed: total revenue $78-80M, clinical tests 43-45k, net loss ~$105M.
- Second Medicare coverage in six months (lung cancer surveillance) follows prior breast cancer win.
- CEO states 'Win-in-MRD' strategy working; clinical revenue expected to grow five-fold in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312526211850/0001193125-26-211850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312526211850/psnl-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer